Abstract |
STUDY RESULTS:
Statin use is CKD patients has been associated with a certain efficacy of cardiovascular disease prevention in several uncontrolled trials, and one randomized trial in renal transplant recipients. Several other large-scale randomized trials in CKD patients [4D ( atorvastatin), AURORA ( rosuvastatin) and SHARP ( simvastatin/ ezetimib) are currently underway. The results of these trials will permit evidence-based medicinal arguments justifying life-long clinical use of statins for cardiovascular prevention in CKD patients with progressive renal dysfunction, but data are inconclusive. OTHER POSSIBLE EFFECTS: Clinically relevant plethoric effects associated with statin therapy in CKD patients might be restricted to the decrease of inflammation and oxidative stress.
|
Authors | Ziad A Massy, Michel Andréjak |
Journal | Presse medicale (Paris, France : 1983)
(Presse Med)
Vol. 33
Issue 17
Pg. 1207-12
(Oct 09 2004)
ISSN: 0755-4982 [Print] France |
Vernacular Title | Intérêt des statines en néphrologie. |
PMID | 15523292
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
Topics |
- Chronic Disease
- Clinical Trials as Topic
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Kidney Diseases
(drug therapy)
- Nephrology
(trends)
- Risk Factors
|